Stock Fundamentals

Company Information

Company Name
BioNTech SE
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
ISIN: US09075V1026
CIK: 0001776985
CUSIP: 09075V102
Currency: USD
Full Time Employees: 7,807
Phone: 49 6131 9084
Fiscal Year End: December
IPO Date: Oct 10, 2019
Description:

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Address:

An der Goldgrube 12, Mainz, Germany, 55131

Directors & Officers

Name Title Year Born
Dr. Ugur Sahin M.D. Co-Founder, CEO & Chair of the Management Board 1965
Dr. Ozlem Tureci M.D. Co-Founder, Chief Medical Officer & Member of Management Board 1967
Mr. Ramon Zapata-Gomez CFO & Member of Management Board 1974
Dr. Sierk Pötting Ph.D. MD, COO & Member of Management Board 1973
Dr. James Timothy Patrick Ryan Ph.D. Chief Legal & Business Officer and Member of the Management Board 1975
Ms. Annemarie Hanekamp Chief Commercial Officer & Member of Management Board 1980
Ms. Kylie Jimenez Chief People Officer & Member of Management Board 1976
Ms. Lisa Birringer Senior Vice President of Global Financial Reporting & Accounting NA
Mr. Douglas Maffei Ph.D. Vice President of Strategy & Investor Relations NA
Jasmina Alatovic Vice President Corporate Communications NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 22, 2026 Sierk Poetting N/A Sale 50.00K $110.56 $5.53M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
T. Rowe Price Investment Management,Inc. 5.86M Mar 31, 2026 2.32% $0.36 -22.65%
FMR Inc 5.71M Mar 31, 2026 2.26% $0.03 -3.78%
PRIMECAP Management Company 3.79M Mar 31, 2026 1.50% $0.27 -0.17%
Flossbach von Storch AG 3.68M Mar 31, 2026 1.46% $1.53 -12.29%
Dodge & Cox 3.68M Mar 31, 2026 1.45% $0.18 1.72%
BlackRock Inc 1.66M Mar 31, 2026 0.66% $0.00 31.84%
BNP Paribas Arbitrage, SA 1.65M Mar 31, 2026 0.65% $0.07 4.54%
Temasek Holdings Ltd. 1.51M Mar 31, 2026 0.60% $0.44 0.00%
Citadel Advisors Llc 951.37K Mar 31, 2026 0.38% $0.01 37.45%
Bank of America Corp 903.03K Mar 31, 2026 0.36% $0.01 17.89%
GSK PLC 889.82K Mar 31, 2026 0.35% $13.20 0.00%
Baillie Gifford & Co Limited. 882.57K Mar 31, 2026 0.35% $0.08 -29.10%
First Trust Advisors L.P. 839.99K Mar 31, 2026 0.33% $0.05 116.01%
UBS Asset Mgmt Americas Inc 784.00K Mar 31, 2026 0.31% $0.01 213.18%
Massachusetts Financial Services Company 670.51K Mar 31, 2026 0.27% $0.02 0.00%
Long Focus Capital Management, LLC 624.00K Mar 31, 2026 0.25% $1.46 22.92%
Candriam Luxembourg S.C.A. 488.37K Mar 31, 2026 0.19% $0.23 -19.27%
Morgan Stanley - Brokerage Accounts 482.41K Mar 31, 2026 0.19% $0.00 -29.33%
DekaBank Deutsche Girozentrale 481.40K Mar 31, 2026 0.19% $0.07 -0.95%
Victory Capital Management Inc. 476.92K Mar 31, 2026 0.19% $0.03 19.05%

Shares Statistics

Shares Outstanding: 252.88M
Shares Float: 110.10M
% Insiders: 5,712.90%
% Institutions: 2,048.90%
Short % Float: 3.40%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 FvS SICAV Multiple Opportunities F 2.73M 1.08% ▲ 0.00% Feb 28, 2026
2 Fidelity Contrafund 2.55M 1.01% ▲ 25.03% Apr 30, 2026
3 Dodge & Cox International Stock I 2.52M 1.00% ▲ 0.00% Mar 31, 2026
4 T. Rowe Price Capital Appreciation 2.27M 0.90% ▲ 0.00% Apr 30, 2026
5 Vanguard Capital Opportunity Inv 2.19M 0.87% ▼ 0.12% Mar 31, 2026
6 FvS Multiple Opportunities II I 1.13M 0.45% ▲ 0.00% Feb 28, 2026
7 T. Rowe Price US Mid-Cap Growth Equity 1.02M 0.40% ▼ 0.09% Mar 31, 2026
8 T. Rowe Price Mid-Cap Growth 1.02M 0.40% ▼ 0.04% Apr 30, 2026
9 Fidelity Contrafund Commingled Pl Cl S 989.67K 0.39% ▲ 35.54% Apr 30, 2026
10 PRIMECAP Odyssey Aggressive Growth 919.15K 0.36% ▲ 0.00% Mar 31, 2026

Valuation Metrics

Enterprise Value: $6.81B
Trailing P/E: 0.00
Forward P/E: 7.04

Financial Highlights

Market Cap: $23.14B
EBITDA: $-1.19B
PEG Ratio: $0.05
Book Value: $84.44
Earnings/Share: $-5.77
Profit Margin: -44.64%
Operating Margin: -576.63%
ROA (TTM): -4.18%
ROE (TTM): -6.66%
Revenue (TTM): $2.81B
Revenue/Share (TTM): $11.45
Earnings Growth (YOY): -43.20%
Revenue Growth (YOY): -35.40%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 7.54x 0.01x 0.13x -45.74x -0.43x
2024-12-31 7.45x 0.01x 0.14x -99.86x -0.69x
2023-12-31 9.43x 0.01x 0.12x 88.96x 0.16x
2022-12-31 7.43x 0.01x 0.14x 799.08x 0.02x
2021-12-31 4.33x 0.03x 0.25x 2,715.05x 0.02x
2020-12-31 2.75x 0.18x 0.41x -44.21x -2.28x
2019-12-31 4.05x 0.16x 0.38x -107.17x -0.53x
2018-12-31 3.56x 0.04x 0.59x -30.30x -0.49x
2017-12-31 1.20x -0.39x 1.13x -94.06x -0.26x
2016-12-31 5.62x 0.10x 0.92x N/A N/A

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about BNTX.US!